249 related articles for article (PubMed ID: 29581109)
1. B-cell tumor development in
Mouly E; Ghamlouch H; Della-Valle V; Scourzic L; Quivoron C; Roos-Weil D; Pawlikowska P; Saada V; Diop MK; Lopez CK; Fontenay M; Dessen P; Touw IP; Mercher T; Aoufouchi S; Bernard OA
Blood Adv; 2018 Mar; 2(6):703-714. PubMed ID: 29581109
[TBL] [Abstract][Full Text] [Related]
2. SIGLEC-G deficiency increases susceptibility to develop B-cell lymphoproliferative disorders.
Simonetti G; Bertilaccio MT; Rodriguez TV; Apollonio B; Dagklis A; Rocchi M; Innocenzi A; Casola S; Winkler TH; Nitschke L; Ponzoni M; Caligaris-Cappio F; Ghia P
Haematologica; 2014 Aug; 99(8):1356-64. PubMed ID: 24859880
[TBL] [Abstract][Full Text] [Related]
3. Role of Bruton's tyrosine kinase in B cells and malignancies.
Pal Singh S; Dammeijer F; Hendriks RW
Mol Cancer; 2018 Feb; 17(1):57. PubMed ID: 29455639
[TBL] [Abstract][Full Text] [Related]
4. Disparate effects of Shb gene deficiency on disease characteristics in murine models of myeloid, B-cell, and T-cell leukemia.
Jamalpour M; Li X; Gustafsson K; Tyner JW; Welsh M
Tumour Biol; 2018 Apr; 40(4):1010428318771472. PubMed ID: 29792386
[TBL] [Abstract][Full Text] [Related]
5. Ten-Eleven-Translocation 2 (TET2) negatively regulates homeostasis and differentiation of hematopoietic stem cells in mice.
Ko M; Bandukwala HS; An J; Lamperti ED; Thompson EC; Hastie R; Tsangaratou A; Rajewsky K; Koralov SB; Rao A
Proc Natl Acad Sci U S A; 2011 Aug; 108(35):14566-71. PubMed ID: 21873190
[TBL] [Abstract][Full Text] [Related]
6. Non-catalytic Roles of Tet2 Are Essential to Regulate Hematopoietic Stem and Progenitor Cell Homeostasis.
Ito K; Lee J; Chrysanthou S; Zhao Y; Josephs K; Sato H; Teruya-Feldstein J; Zheng D; Dawlaty MM; Ito K
Cell Rep; 2019 Sep; 28(10):2480-2490.e4. PubMed ID: 31484061
[TBL] [Abstract][Full Text] [Related]
7. Tet2 loss leads to hypermutagenicity in haematopoietic stem/progenitor cells.
Pan F; Wingo TS; Zhao Z; Gao R; Makishima H; Qu G; Lin L; Yu M; Ortega JR; Wang J; Nazha A; Chen L; Yao B; Liu C; Chen S; Weeks O; Ni H; Phillips BL; Huang S; Wang J; He C; Li GM; Radivoyevitch T; Aifantis I; Maciejewski JP; Yang FC; Jin P; Xu M
Nat Commun; 2017 Apr; 8():15102. PubMed ID: 28440315
[TBL] [Abstract][Full Text] [Related]
8. Tet2 restrains inflammatory gene expression in macrophages.
Cull AH; Snetsinger B; Buckstein R; Wells RA; Rauh MJ
Exp Hematol; 2017 Nov; 55():56-70.e13. PubMed ID: 28826859
[TBL] [Abstract][Full Text] [Related]
9. Microbial signals drive pre-leukaemic myeloproliferation in a Tet2-deficient host.
Meisel M; Hinterleitner R; Pacis A; Chen L; Earley ZM; Mayassi T; Pierre JF; Ernest JD; Galipeau HJ; Thuille N; Bouziat R; Buscarlet M; Ringus DL; Wang Y; Li Y; Dinh V; Kim SM; McDonald BD; Zurenski MA; Musch MW; Furtado GC; Lira SA; Baier G; Chang EB; Eren AM; Weber CR; Busque L; Godley LA; Verdú EF; Barreiro LB; Jabri B
Nature; 2018 May; 557(7706):580-584. PubMed ID: 29769727
[TBL] [Abstract][Full Text] [Related]
10. Antibiotic treatment ameliorates Ten-eleven translocation 2 (TET2) loss-of-function associated hematological malignancies.
Zeng H; He H; Guo L; Li J; Lee M; Han W; Guzman AG; Zang S; Zhou Y; Zhang X; Goodell MA; King KY; Sun D; Huang Y
Cancer Lett; 2019 Dec; 467():1-8. PubMed ID: 31563562
[TBL] [Abstract][Full Text] [Related]
11. Tet2 promotes pathogen infection-induced myelopoiesis through mRNA oxidation.
Shen Q; Zhang Q; Shi Y; Shi Q; Jiang Y; Gu Y; Li Z; Li X; Zhao K; Wang C; Li N; Cao X
Nature; 2018 Feb; 554(7690):123-127. PubMed ID: 29364877
[TBL] [Abstract][Full Text] [Related]
12. A Therapeutic Strategy for Preferential Targeting of TET2 Mutant and TET-dioxygenase Deficient Cells in Myeloid Neoplasms.
Guan Y; Tiwari AD; Phillips JG; Hasipek M; Grabowski DR; Pagliuca S; Gopal P; Kerr CM; Adema V; Radivoyevitch T; Parker Y; Lindner DJ; Meggendorfer M; Abazeed M; Sekeres MA; Mian OY; Haferlach T; Maciejewski JP; Jha BK
Blood Cancer Discov; 2021 Mar; 2(2):146-161. PubMed ID: 33681816
[No Abstract] [Full Text] [Related]
13. Germline TET2 loss of function causes childhood immunodeficiency and lymphoma.
Stremenova Spegarova J; Lawless D; Mohamad SMB; Engelhardt KR; Doody G; Shrimpton J; Rensing-Ehl A; Ehl S; Rieux-Laucat F; Cargo C; Griffin H; Mikulasova A; Acres M; Morgan NV; Poulter JA; Sheridan EG; Chetcuti P; O'Riordan S; Anwar R; Carter CR; Przyborski S; Windebank K; Cant AJ; Lako M; Bacon CM; Savic S; Hambleton S
Blood; 2020 Aug; 136(9):1055-1066. PubMed ID: 32518946
[TBL] [Abstract][Full Text] [Related]
14. Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation.
Moran-Crusio K; Reavie L; Shih A; Abdel-Wahab O; Ndiaye-Lobry D; Lobry C; Figueroa ME; Vasanthakumar A; Patel J; Zhao X; Perna F; Pandey S; Madzo J; Song C; Dai Q; He C; Ibrahim S; Beran M; Zavadil J; Nimer SD; Melnick A; Godley LA; Aifantis I; Levine RL
Cancer Cell; 2011 Jul; 20(1):11-24. PubMed ID: 21723200
[TBL] [Abstract][Full Text] [Related]
15. Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignancies.
Li Z; Cai X; Cai CL; Wang J; Zhang W; Petersen BE; Yang FC; Xu M
Blood; 2011 Oct; 118(17):4509-18. PubMed ID: 21803851
[TBL] [Abstract][Full Text] [Related]
16. [TET2 as a gatekeeper for hematologic malignancies].
Muto H; Sakata-Yanagimoto M; Chiba S
Rinsho Ketsueki; 2015 Jun; 56(6):651-6. PubMed ID: 26256875
[TBL] [Abstract][Full Text] [Related]
17. ZAP-70 enhances B-cell-receptor signaling despite absent or inefficient tyrosine kinase activation in chronic lymphocytic leukemia and lymphoma B cells.
Gobessi S; Laurenti L; Longo PG; Sica S; Leone G; Efremov DG
Blood; 2007 Mar; 109(5):2032-9. PubMed ID: 17038529
[TBL] [Abstract][Full Text] [Related]
18. Targeting the B-cell receptor signaling pathway in B lymphoid malignancies.
Buchner M; Müschen M
Curr Opin Hematol; 2014 Jul; 21(4):341-9. PubMed ID: 24811161
[TBL] [Abstract][Full Text] [Related]
19. The TET2 interactors and their links to hematological malignancies.
Pan F; Weeks O; Yang FC; Xu M
IUBMB Life; 2015 Jun; 67(6):438-45. PubMed ID: 26099018
[TBL] [Abstract][Full Text] [Related]
20. AID and TET2 co-operation modulates FANCA expression by active demethylation in diffuse large B cell lymphoma.
Jiao J; Jin Y; Zheng M; Zhang H; Yuan M; Lv Z; Odhiambo W; Yu X; Zhang P; Li C; Ma Y; Ji Y
Clin Exp Immunol; 2019 Feb; 195(2):190-201. PubMed ID: 30357811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
